» Articles » PMID: 28742676

Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy

Overview
Journal Obstet Gynecol
Date 2017 Jul 26
PMID 28742676
Citations 175
Affiliations
Soon will be listed here.
Abstract

Opioid use in pregnancy has escalated dramatically in recent years, paralleling the epidemic observed in the general population. To combat the opioid epidemic, all health care providers need to take an active role. Pregnancy provides an important opportunity to identify and treat women with substance use disorders. Substance use disorders affect women across all racial and ethnic groups and all socioeconomic groups, and affect women in rural, urban, and suburban populations. Therefore, it is essential that screening be universal. Screening for substance use should be a part of comprehensive obstetric care and should be done at the first prenatal visit in partnership with the pregnant woman. Patients who use opioids during pregnancy represent a diverse group, and it is important to recognize and differentiate between opioid use in the context of medical care, opioid misuse, and untreated opioid use disorder. Multidisciplinary long-term follow-up should include medical, developmental, and social support. Infants born to women who used opioids during pregnancy should be monitored for neonatal abstinence syndrome by a pediatric care provider. Early universal screening, brief intervention (such as engaging a patient in a short conversation, providing feedback and advice), and referral for treatment of pregnant women with opioid use and opioid use disorder improve maternal and infant outcomes. In general, a coordinated multidisciplinary approach without criminal sanctions has the best chance of helping infants and families.

Citing Articles

Abnormal Urine Drug Screens in Pregnancy- Opportunity for Laboratory Stewardship.

Chokkalla A, Malik S, Ibrahim R, Devaraj S EJIFCC. 2025; 36(1):83-87.

PMID: 40061067 PMC: 11886620.


Buprenorphine induces human fetal membrane sterile inflammation.

Lynn T, Kelleher M, Georges H, McCauley E, Logan R, Yonkers K J Reprod Immunol. 2025; 168:104445.

PMID: 39914058 PMC: 11890952. DOI: 10.1016/j.jri.2025.104445.


Effect of E-learning clinical management of substance-dependent pregnant women on the knowledge and clinical skill performance of midwives: a randomized controlled trial.

Heidarian H, Mehrabi M, Ghaemmaghami P, Janghorban R BMC Pregnancy Childbirth. 2025; 25(1):11.

PMID: 39780073 PMC: 11707862. DOI: 10.1186/s12884-024-07130-6.


Buprenorphine and postpartum contraception utilization among people with opioid use disorder: a multi-state analysis.

Xu K, Bello J, Buss J, Jones H, Bierut L, Stwalley D Addict Sci Clin Pract. 2025; 20(1):1.

PMID: 39762993 PMC: 11702041. DOI: 10.1186/s13722-024-00530-1.


"They talked to me like I was dirt under their feet:" Treatment and withdrawal experiences of incarcerated pregnant people with opioid use disorder in four U.S. states.

Sufrin C, Ziv T, Dayton L, Latkin C, Kramer C SSM Qual Res Health. 2025; 6.

PMID: 39748911 PMC: 11694624. DOI: 10.1016/j.ssmqr.2024.100453.